Phathom Pharmaceuticals, Inc. (PHAT): Cost of Revenue

Annual figures by period end, from SEC filings.

$22.60M

Year ended 2025-12-31

$40.93M

Trailing 12 months to 2026-06-30

2022-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$22.60M	+183.4%	2026-02-26, From 2025-01-01
2024-12-31	$7.97M	n/m	2026-02-26, From 2024-01-01
2023-12-31	$167.0K	n/a	2025-03-06, From 2023-01-01
2022-12-31	$0	n/a	2024-06-14, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Phathom Pharmaceuticals, Inc. (PHAT)	2025-12-31	$22.60M	+183.4%
Cryoport, Inc. (CYRX)	2025-12-31	$93.12M	+6.9%
Lifevantage Corp (LFVN)	2026-06-30	$40.97M	-8.7%
Maravai Lifesciences Holdings, Inc. (MRVI)	2025-12-31	$151.75M	+0.6%
Rhythm Pharmaceuticals, Inc. (RYTM)	2025-12-31	$19.49M	+45.8%
Liquidia Corp (LQDA)	2024-12-31	$5.88M	+103.6%
Heron Therapeutics, Inc. (HRTX)	2025-12-31	$41.35M	+7.0%
Macrogenics Inc (MGNX)	2025-12-31	$0	-100.0%
Elite Pharmaceuticals Inc (ELTP)	2026-03-31	$73.85M	+68.0%

Compare PHAT, CYRX, LFVN, MRVI side by side · Screen every company in Pharmaceutical Preparations ↗